A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Systemic Lupus Erythematosus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Climb Bio, Inc.
- Last updated on ClinicalTrials.gov
- March 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 2
- Climb Bio Investigative Site #100104 · Allen, TX
- Climb Bio Investigative Site #100101 · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.